Skip to main content
OpenTrials
Completed

NCT Number: NCT03172572

A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers

RATIONALE: Minimally-invasive pancreatoduodenectomy (MIPD), either laparoscopic or robot-assisted, has been suggested as a valuable alternative to open pancreatoduodenectomy (OPD). The generalizability of the current literature is, however, unknown since randomized studies are lacking, and current data are published from few, very high volume centers and selection bias with a lack of case-matched series. International studies are lacking completely.

OBJECTIVE: To compare outcomes of MIPD versus open pancreatoduodenectomy (OPD), in high-volume European pancreas centers (>10 MIPDs per year, total >20 PDs per year).

METHODS: A retrospective multicenter propensity-score matched cohort study including all consecutive patients who underwent MIPD (or MI total pancreatectomy) between January 2012 and December 2016, for pancreatic head, bile duct, or duodenal cancer or cysts except chronic pancreatitis. Predefined electronic case report forms will be disseminated amongst participating centers. Participants are responsible for their own data collection. Matching of MIPD cases (collected from participating centers) to OPD controls (extracted from Dutch and German national registries) will be based on propensity scores determined by logistic regression including preoperative variables: year of surgery, demographics, BMI, ASA, comorbidities, tumor size, tumor etiology (diagnosis), and multivisceral resection. Primary outcome is 90-day major morbidity(Clavien-Dindo ≥ 3a). Secondary outcomes are 90-day postoperative events including: pancreatic fistula, length of hospital stay, R0 (microscopically negative) resection margin, malignant lymph node ratio, days to adjuvant therapy and overall survival.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sjors Klompmaker

Amsterdam, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Indication for open or minimally invasive pancreatoduodenectomy
  • Pancreatic head, bile duct, or duodenal cancer or cysts

Exclusion criteria

  • Chronic pancreatitis without suspected solid tumor.

Treatment and study plan

Minimally invasive pancreatoduodenectomy

Procedure

Laparoscopic, robot-assisted, or hybrid resection

Open pancreatoduodenectomy

Procedure

Open resection

Primary outcomes

  1. Major morbidity

    Time frame: 90-days

    Clavien-Dindo grade 3a-5 complications

Secondary outcomes

  1. Pancreatic fistulae

    Time frame: 90-days

    ISGPS 2017 definition

  2. Length of stay

    Time frame: 90-days

    length of hospital stay

  3. Radical resection rate

    Time frame: 90-days

    R0/R1/R2 classification

  4. Malignant lymph node ratio

    Time frame: 90-days

    Malignant/ non-malignant lymph nodes

  5. time to adjuvant therapy

    Time frame: 90-days

    Resection to adjuvant chemo(-radio) therapy

  6. Overall survival

    Time frame: 90-days

Sponsors and collaborators

Lead sponsor

S (Sjors) Klompmaker, MD

Other

Registry information

Official study title

Outcomes After Minimally Invasive or Open Pancreatoduodenectomy in High-volume Centers; a Pan-European Retrospective Propensity-score Matched Cohort Study

Acronym: MI-PD

Important dates

Study start
2017
Primary completion
2017
Study completion
2018
First posted
Jun 1, 2017
Registry last updated
Jun 27, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.